Maresin 2 - CAS:1639809-46-3

您当前的位置：

Maresin 2

目录号 : KCM11855 CAS No. : 1639809-46-3 纯度 : ≥95%

Data Sheet 产品使用指南

Docosahexaenoic acid (DHA; ) is an ω-3 fatty acid that is abundant in the brain and the retina and is known to be important in early development. Maresin 2 (MaR2) is a 13R,14S-dihydroxy DHA formed by recombinant human macrophage 12-lipoxygenase and soluble epoxide hydrolase co-incubated with DHA. At 1 ng/mouse, MaR2 was shown to reduce neutrophil infiltration by 40% in a mouse model of peritonitis, and at 10 pM, MaR2 can enhance human macrophage phagocytosis of zymosan A by 90%. Analytical and biological comparisons of synthetic MaR2 with endogenously derived MaR2 have confirmed its identity as matching the natural product.

规格	价格	是否有货	数量
10 μg		In-stock
25μg		In-stock
50μg		In-stock
100μg		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

BI-765423 In-stock
Crebankitug In-stock
Levilimab In-stock
Sarilumab In-stock
Pacibekitug In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury.

体外研究

When Maresin 2 (200 nM) is combined with 10 ng/mL TNFα/IFNγ, it promotes scratch wound healing and migration efficiency in HT29/B6 intestinal epithelial cells.
Maresin 2 (200 nM; 16 h) synergistically activates the FAK-Src-paxillin and talin-vinculin focal adhesion signaling axes in HT29/B6 intestinal epithelial cells when combined with 10 ng/mL TNFα/IFNγ, promoting pro-migratory signaling at the wound front.

Immunofluorescence

Cell Line:	HT29/B6 human intestinal epithelial cells
Concentration:	200 nM
Incubation Time:	16 hours
Result:	Increased numbers of vinculin-containing focal adhesions at the leading edge of spreading cells significantly relative to TNFα/IFNγ alone (P < 0.01).

体内研究

Maresin 2 (2 ng/g body weight; intraperitoneal injection; single dose; 24 hours post-trauma) significantly increased the colonic mucosal wound healing rate to 47.67% at 72 hours post-injury in a biopsy-induced colonic mucosal injury model in C57BL/6 mice [1].
Maresin 2 (2 ng/g body weight; intraperitoneal injection; administered on days 0, 2, 4, 6, and 8; total 5 doses) significantly reduced disease activity and colonic mucosal damage in a 5% DSS-induced colitis model of C57BL/6 mice, with a histological colitis score of 3.951.
Maresin 2 (1-10 ng per rat; intraperitoneal injection; administered daily for 2 consecutive days followed by every other day; days 14-32 post streptozotocin induction) significantly alleviated mechanical allodynia in streptozotocin-induced male Wistar diabetic rats (at doses of 1, 3, and 10 ng/rat), improved anxiety-like behaviors at a dose of 3 ng/rat, and normalized IL-1β levels in the spinal cord and prefrontal cortex.
Maresin 2 (1 ng per mouse; intravenous injection; for 4 days) exhibits protective effects against ovalbumin-induced asthma in female BALB/c mice, mitigating airway inflammation, Th2 immune response, NLRP3 inflammasome activation, and oxidative stress.
Maresin 2 (1-10 ng; subarachnoid; single injection) significantly alleviates the acute and inflammatory phases of formalin-induced orofacial nociception in rats.
Maresin 2 (10 ng; administered twice on postoperative days 1 and 3) can prevent the development of thermal and mechanical hyperalgesia in a rat postoperative orofacial pain model.

Animal Model:	C57BL/6 (10 to 12 weeks old, male and female, biopsy-induced colonic mucosal injury)
Dosage:	2 ng/g body weight
Administration:	i.p.; single injection; 24 h post-wounding
Result:	Increased colonic mucosal wound healing to 47.67% at 72 h post-wounding compared to 34.58% in vehicle control mice (P < 0.01).

Animal Model:

C57BL/6 (10 to 12 weeks old, male and female, 5% DSS-induced colitis)

Dosage:

2 ng/g body weight

Administration:

i.p.; 5 doses on days 0, 2, 4, 6, and 8

Result:

Reduced disease activity index (DAI) scores at multiple time points (P < 0.01, P < 0.001, P < 0.0001).
Reduced histological colitis score to 3.951 compared to 5.474 in vehicle control mice (P < 0.05).
Decreased mucosal ulceration/erosion and infiltrating immune cells.

Animal Model:

Wistar rats (male, 180-240 g, streptozotocin-induced type 1 diabetes mellitus)

Dosage:

1 ng/rat; 3 ng/rat; 10 ng/rat

Administration:

i.p.; daily for 2 consecutive days, then alternate days; days 14-32 post-streptozotocin induction

Result:

Failed to alter mechanical threshold in diabetic rats after acute treatment.
Showed significant improvement in mechanical threshold at 3 ng dose on day 20 post-streptozotocin induction (p = 0.0017).
Showed significant improvement in mechanical threshold at all doses (1, 3, 10 ng) on day 26 post-streptozotocin induction (p < 0.05) compared to vehicle-treated diabetic rats.
Significantly increased time spent in open arms (p = 0.05) and decreased time spent in closed arms (p < 0.05) in elevated plus-maze test at 3 ng dose compared to vehicle-treated diabetic rats.
Did not alter depressive-like behavior in modified forced swimming test or locomotor/exploratory behavior in open-field test at any dose.
Reversed elevated IL-1β levels in spinal cord at 3 ng (p = 0.0170) and 10 ng (p = 0.0445) doses compared to vehicle-treated diabetic rats.
Reversed elevated IL-1β levels in prefrontal cortex at all doses (1 ng, p = 0.0151; 3 ng, p = 0.0266; 10 ng, p = 0.0201) compared to vehicle-treated diabetic rats.
Did not affect IL-1β levels in hippocampus, hyperglycemia, or low weight gain in diabetic rats at any dose.

Animal Model:

BALB/c (female, 6-8 weeks old, 20-25 g, specific pathogen-free, ovalbumin-induced asthma model)

Dosage:

1 ng per mouse

Administration:

i.v.; daily; 4 days

Result:

Reduced airway inflammation score (P < 0.05) and goblet cell proliferation score (P < 0.05).
Decreased lung tissue expression of MPO (P < 0.01) and Ly-6G (P < 0.05).
Lowered total inflammatory cell count (P < 0.05), neutrophil count (P < 0.05), and eosinophil count (P < 0.05) in BALF.
Reduced BALF levels of Th2 cytokines IL-4 (P < 0.01), IL-5 (P < 0.01), and IL-13 (P < 0.01).
Lowered serum total IgE (P < 0.01) and ovalbumin-specific IgE (P < 0.05).
Decreased lung tissue expression of NLRP3 (P < 0.05), ASC (P < 0.05), and Caspase-1 (P < 0.05).
Reduced BALF levels of IL-1β (P < 0.05) and IL-18 (P < 0.05).
Decreased lung tissue MDA levels (P < 0.05) and increased GSH (P < 0.05) and SOD (P < 0.01) levels.
Reduced lung tissue ICAM-1 expression (P < 0.01).

分子式

C₂₂H₃₂O₄

分子量

360.49

CAS号

1639809-46-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-80°C

纯度： ≥95%

Data Sheet

产品使用指南

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 0 篇科研文献

The molarity calculator equation

The dilution calculator equation